LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and...
Read More Details
Finally We wish PressBee provided you with enough information of ( Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 )
Also on site :
- Why the JPY got bid across the board?
- CKPower Expands RECs Operations to Accelerate Global Clean Energy Adoption
- Europe considering deploying air and naval forces to Ukraine – WaPo